Supplementary Methods

Cell line models
Leukemia cell lines (KASUMI-1, NB-4, OCI-AML5, OCI-AML3, ME-1, MV4-11 and K-562) were purchased from the German cell line repository (DSMZ) and grown according to standard protocols.
Additional patient and healthy sample information
Patient samples were collected at first diagnosis and chosen from the larger AMLSG_07-04 study cohort by applying the following criteria: availability of RNA material, high RNA quality and availability of gene expression data. Mononuclear cells of AML samples were enriched via Ficoll-Hypaque density gradient, and the percentage of leukemic blasts was >85%. For the quantification of hsa_circ_0075001, 46 cytogenetically normal AML cases were selected of which 23 carried an NPM1 mutation. For RNA-Seq, 10 cytogenetically normal AML cases were selected of which 5 carried an NPM1 mutation.
For PCR experiments, the healthy cells were derived from the peripheral blood-derived mononuclear cell fraction of healthy donors.
RNA isolation, quality control and reverse transcription
RNA was isolated from cell lines and patient samples using the AllPrep DNA/RNA/miRNA Universal Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. RNA integrity was assessed with the Agilent 2100 Bioanalyzer using the Agilent RNA 6000 Nano Kit (Agilent Technologies, Santa Clara, CA, USA) and only samples with an RNA Integrity Number (RIN) of 7.5 or higher were included in the study. Using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA), 1 μg total cell line RNA or 700 ng total patient RNA was converted to single-stranded cDNA with the use of random primers.
TOPO cloning reaction and cycle sequencing reaction (CSR)
Polymerase chain reaction (PCR) products were cloned into a TOPO vector using the TOPO® TA Cloning® Kit for Sequencing (Invitrogen, Carlsbad, CA, USA) and transformed into TOP10 E.coli cells according to the manufacturer's instructions. Plasmid DNA was isolated using a QIAprep Spin Miniprep Kit (QIAGEN) and 300 ng were used in the cycle sequencing reaction (CSR). The CSR was performed using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems).
PCR and quantitative real-time PCR (qPCR)
PCR primers were used at a final concentration of 200 nM, and 0.5 units of the HotStarTaq DNA polymerase were present per 40 cycle reaction. Primers for qPCR were used at a final concentration of 500 nM and primer sequences are listed in Supplementary Table 1 . qPCR was performed on the 7900HT Fast Real-Time PCR System (Applied Biosystems) and for data analysis the 7900HT SDS 2.3 software (Applied Biosystems) was used. All values are means of two replicates and results were normalized to β-Actin (ACTB). qPCR efficiencies were calculated by creating a standard curve with 10-fold serial dilutions with 6 points of DNA templates. For all qPCR reactions used in the analysis, the efficiency was >99% and R 2 was >0.99.
Gene expression profiling
Gene expression data of 46 bone marrow or peripheral blood samples from AML patients were obtained as previously reported using GeneChip® Human Genome U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, CA, USA) 1-3 .
Databases used for pathway analysis
Pathway analysis was performed using the iPathwayGuide web application (Advaita, Plymouth, MI, USA). Statistical thresholds were set at p<0. 05 
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